XmAb7195: Phase Ia data

Top-line data from 30 healthy volunteers in part 1 of a 2-part double-blind, placebo-controlled, U.S. Phase Ia trial showed that single doses of 0.3, 1 and 3 mg/kg IV XmAb7195 led to a reduction in fr...